Document Detail


Pharmacokinetic evaluation of capecitabine in breast cancer.
MedLine Citation:
PMID:  23301520     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Capecitabine , an oral prodrug of 5-fluorouracil (5-FU), is adsorbed in its intact form through the intestine and metabolized to 5-FU in tumour cells. In metastatic breast cancer (MBC), capecitabine is an effective and well-tolerated therapeutic option both in monotherapy and in combination with chemotherapeutic or molecular-targeted agents.
AREAS COVERED: We summarized data on pharmacokinetics and pharmacodynamics of capecitabine. We also produced a general review of the most relevant clinical studies of capecitabine in MBC. A literature search was performed using PubMed database including selected articles published in English language up to October 2012.
EXPERT OPINION: The unique pharmacodynamic/pharmacokinetic features represent the bases of the reduced toxicity and the activity of capecitabine in several tumours. Although during the past 10 years there has been an increasing use of this drug in MBC both as single agent and in combination, encouraging results of well tolerated and active combinations with novel agents will lead to a more extensive and protracted use of capecitabine. In view of this, some aspects should be further clarified such as the optimal starting dose and the introduction of alternative schedules of treatment.
Authors:
Gennaro Daniele; Marianna Gallo; Maria Carmela Piccirillo; Pasqualina Giordano; Amelia D'Alessio; Antonia Del Giudice; Maria Libera La Porta; Francesco Perrone; Nicola Normanno; Antonella De Luca
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-10
Journal Detail:
Title:  Expert opinion on drug metabolism & toxicology     Volume:  9     ISSN:  1744-7607     ISO Abbreviation:  Expert Opin Drug Metab Toxicol     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-16     Completed Date:  2013-10-17     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101228422     Medline TA:  Expert Opin Drug Metab Toxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  225-35     Citation Subset:  IM    
Affiliation:
Clinical Trials Unit, INT-Fondazione Pascale, Naples, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antimetabolites, Antineoplastic / pharmacokinetics*,  therapeutic use
Breast Neoplasms / drug therapy*,  metabolism*
Deoxycytidine / analogs & derivatives*,  pharmacokinetics,  therapeutic use
Female
Fluorouracil / analogs & derivatives*,  pharmacokinetics,  therapeutic use
Humans
Prodrugs / pharmacokinetics*,  therapeutic use
Randomized Controlled Trials as Topic / methods,  trends
Chemical
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Prodrugs; 51-21-8/Fluorouracil; 6804DJ8Z9U/capecitabine; 951-77-9/Deoxycytidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Design and Biological Evaluation of Cell-Penetrating Peptide-Doxorubicin Conjugates as Prodrugs.
Next Document:  Stable isotope- and mass spectrometry-based metabolomics as tools in drug metabolism: a study expand...